Many cancer treatments are notoriously savage on the body. Drugs often attack both healthy cells and tumor cells, causing a plethora of side effects. Immunotherapies that help the immune system recognize and attack cancer cells are no different. Though they have prolonged the lives of countless patients, they work in only a subset of patients. One study found that fewer than 30% of breast cancer patients respond to one of the most common forms of immunotherapy.
But what if drugs could be engineered to attack only tumor cells and spare the rest of the body? To that end, my colleagues and I at the University of Chicago’s Pritzker School of Molecular Engineering have designed a method to keep one promising cancer drug from wreaking havoc by “masking” it until it reaches a tumor.
The promise of IL-12
Cytokines are proteins that can modulate how the immune system responds to threats. One way they do this is by activating killer T cells, a type of white blood cells that can attack cancer cells. Because cytokines can train the immune system to kill tumors, this makes them very promising as cancer treatments.
One such cytokine is interleukin-12, or IL-12. Though it was discovered more than 30 years ago, IL-12 still isn’t an FDA-approved therapy for cancer patients because of its severe side effects, such as liver damage. This is in part because IL-12 instructs immune cells to produce a large amount of inflammatory molecules that can damage the body.
Scientists have since been working to reengineer IL-12 to be more tolerable while retaining its powerful cancer-killing effects.
Masking the killer
To create a safer version of IL-12, my colleagues and I took advantage of one of the main differences between healthy and cancerous tissue: an excess of growth-promoting enzymes in cancers. Because cancer cells proliferate very rapidly, they overproduce certain enzymes that help them invade the nearby healthy tissue and metastasize to other parts of the body. Healthy cells grow at a much slower pace and produce fewer of these enzymes.
With this in mind, we “masked” IL-12 with a cap that covers the part of the molecule that normally binds to immune cells to activate them. The cap is removed only when it comes into contact with enzymes found in the vicinity of tumors. When these enzymes chop off the cap, IL-12 is reactivated and spurs nearby killer T cells to attack the tumor.
When we applied these masked IL-12 molecules to both healthy and tumor tissue donated by melanoma and breast cancer patients, our results confirmed that only the tumor samples were able to remove the cap. This indicated that masked IL-12 could potentially drive a strong immune response against tumors without causing damage to healthy organs.
We then examined how safe masked IL-12 is by measuring liver damage biomarkers in mice. We found that immune-related side effects typically associated with IL-12 were notably absent in mice treated with masked IL-12 over a period of several weeks, indicating improved safety.
In breast cancer models, our masked IL-12 resulted in a 90% cure rate, while treatment with a commonly used immunotherapy called a checkpoint inhibitor resulted in only a 10% cure rate. In a model of colon cancer, masked IL-12 showed a 100% cure rate.
Our next step is to test the modified IL-12 in cancer patients. While it will take time to bring this encouraging development directly to patients, we believe a promising new treatment is on the horizon.

News
Can our mitochondria help to beat long Covid?
At Cambridge University’s MRC Mitochondrial Biology Unit, Michal Minczuk is one of a growing number of scientists around the world aiming to find new ways of improving mitochondrial health. This line of research could help [...]
Lipid nanoparticles carry gene-editing cancer drugs past tumor defenses
As they grow, solid tumors surround themselves with a thick, hard-to-penetrate wall of molecular defenses. Getting drugs past that barricade is notoriously difficult. Now, scientists at UT Southwestern have developed nanoparticles that can break [...]
Graphene Nanosensor Detects Biomarkers Through Tears
In an article recently published in the journal Talanta, researchers demonstrated a new approach to enable the specific detection of biomarkers in human tear by employing an aptamer-based graphene affinity nanosensor. The ability to detect [...]
How Nanotechnology Can Make a Splash in Aquaculture
Selenium (Se) is an essential element found in aquatic feeds that promotes the proper development, wellbeing, and fitness of marine animals. Selenium can be transformed into nanomaterials that are more easily accessible, absorbed, and consumed by [...]
Super-Resolution Imaging Method For Multiple Fluorescence Microscopy Applications
In an article recently published in the journal Nanotechnology, researchers employed a single particle imaging method for fluorescence excitation with moderate intensity to achieve spatial resolution. Here, the semiconductor nanocrystals were accessed, whose emission lifetimes [...]
Trials to begin on new SA COVID-19 vaccine
A new COVID-19 vaccine developed in South Australia and administered with a needle-free device is to begin human trials. Designed by University of Adelaide researchers the DNA vaccine also targets the Omicron variant of [...]
Towards Carbon Clean Manufacturing with Eco-Friendly Nano-Lubricants
Grinding is an essential manufacturing process, yet the heat due to friction associated with the process causes damage to the part being processed. Lubrication is used to reduce friction; however, traditional petroleum-based lubricants can [...]
Researchers develop hybrid sensor that could help diagnose cancer
A team of researchers from HSE University, Skoltech, MPGU, and MISIS have developed a nanophotonic-microfluidic sensor whose potential applications include cancer detection, monitoring and treatment response assessment. Today, the device can identify gases and [...]
Scientists Develop ‘Nanomachines’ That Can Penetrate And Kill Cancer Cells
Researchers have made a scientific breakthrough with the development of ‘nanomachines’ that can kill cancerous cells. The research team headed by Dr Youngdo Jeong from the Center for Advanced Biomolecular Recognition at the Korea Institute of Science and Technology (KIST) has engineered [...]
Green Method to Make Nanoparticles and Ultrafine Powder
A novel freeze-dissolving approach has been devised that offers greater efficiency and sustainability compared to the classic freeze-drying process to make superfine powder or nanoparticles. In the research published in the journal ACS Sustainable Chemistry & Engineering, sphere-shaped [...]
Participants wanted for study on the regulation of what future AI-driven nanomedicines should look like
Would you like to help in some research on the regulation of what future AI-driven nanomedicines should look like? If so, researchers at the University of Bristol are looking for volunteers to discuss ethical [...]
Could gold nanoparticles help treat cancer?
Gold nanoparticles are minuscule particles made of gold. From drug and gene delivery to photothermal and photodynamic therapies to screening and diagnostic tests to radiation therapy, X-ray imaging and CT scans, these small particles [...]
Carbon Dots Target Nucleolus and Monitor in Real-Time
In an article recently published in the journal Applied Surface Science, the researchers synthesized green fluorescent carbon dots (G-CDs) from 3,5-diaminobenzoic acid and citric acid. The as-prepared G-CDs were used to target the nucleolus and [...]
Green Nanoformulation for Anti-Cancer and Antibacterial Functions
Doxorubicin (DOX) is a powerful anti-cancer medication, and efforts have been made to design nanostructures for delivering it to cancerous cells. The nanostructures increase the cytotoxic effects of DOX on cancerous cells, while reducing the negative effects [...]
New drug delivery system releases therapeutic cargo only when bacteria are present
A team of Brown University researchers has developed a new responsive material that is able to release encapsulated cargo only when pathogenic bacteria are present. The material could be used to make wound dressings [...]
Hairy Cell Leukemia Complicated by Severe COVID-19: A Case Study
Novel three-drug regimen used to manage life-threatening developments. In April 2021, a 42-year-old man reached out to Brian Hill, MD, PhD, for a second opinion after being diagnosed with hairy cell leukemia following a bone [...]